About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The group of Clinical Neuroimmunology - Centre d'Esclerosi Múltiple de Catalunya (Cemcat) at the Vall d'Hebron Institut de Recerca (VHIR) is a multidisciplinary group dedicated to clinical assistance, physical and cognitive rehabilitation, and clinical and basic research on multiple sclerosis (MS). Cemcat is a national but also an international reference center in the clinical assistance of MS patients. The research performed in the group is divided and further combined in clinical and basic research. In addition, basic research has a marked translational character since the ultimate goal of the group is to improve the quality of life of patients suffering from MS, through in-depth knowledge of the pathogenic mechanisms of the disease and the development of new and more effective therapeutic approaches.
IP: Manuel Comabella Lopez Collaborators: Berta Miró Cau, Andreu Vilaseca Jolonch, Elisa Marín Ordovás, Rucsanda Pinteac, Rucsanda Pinteac Funding agency: Instituto de Salud Carlos III Funding: 233750 Reference: PI24/01088 Duration: 01/01/2025 - 31/12/2027
IP: Manuel Comabella Lopez Collaborators: - Funding agency: Asociación Esclerosis Múltiple España Funding: 50000 Reference: EME/PROJECTE/2024/COMABELLA Duration: 30/09/2024 - 30/09/2025
IP: Carmen Espejo Ruiz Collaborators: - Funding agency: Asociación Esclerosis Múltiple España Funding: 25000 Reference: EME/PROJECTE/2024/ESPEJO Duration: 30/10/2024 - 29/10/2026
IP: Isabel Novoa Garcia Collaborators: Joaquim Vives Armengol, Anna Duarri Piqué, Eva Colas Ortega, Oriol Bestard Matamoros, Marta Rosal Fontana, Carmen Espejo Ruiz, Marielle Esteves Coelho, Juan Jose Gonzalez Lopez, Sheyla Pascual Martín, Alejandro Tomasello Weitz, Shirley Guzmán Avilés Funding agency: Instituto de Salud Carlos III Funding: 137460 Reference: PT23/00040 Duration: 01/01/2024 - 31/12/2026
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
The session has helped bring the public an up-to-date perspective on diagnosis, treatments, and the research lines that are transforming the future of patients.
Dr. Xavier Montalban, Dr. Álex Rovira, Dr. Mar Tintoré and Dr. Jaume Sastre Garriga have been recognised in the listing.
Simoa HD1 equipment
We are looking for 100 healthy volunteers aged 18 or over to participate in a project where the usefulness of biomarkers in serum will be evaluated to predict the prognosis of the disease and the response to treatments.
